Public Employees Retirement System of Ohio Buys New Position in Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Public Employees Retirement System of Ohio purchased a new position in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 367,373 shares of the biopharmaceutical company's stock, valued at approximately $606,000. Public Employees Retirement System of Ohio owned 0.19% of Esperion Therapeutics as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Anson Funds Management LP purchased a new position in shares of Esperion Therapeutics during the 3rd quarter worth approximately $540,000. Connor Clark & Lunn Investment Management Ltd. boosted its position in Esperion Therapeutics by 71.0% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 711,278 shares of the biopharmaceutical company's stock worth $1,174,000 after acquiring an additional 295,378 shares during the last quarter. Wasatch Advisors LP grew its stake in Esperion Therapeutics by 38.4% in the 3rd quarter. Wasatch Advisors LP now owns 23,346,013 shares of the biopharmaceutical company's stock worth $38,521,000 after acquiring an additional 6,483,070 shares during the period. Wellington Management Group LLP raised its holdings in shares of Esperion Therapeutics by 66.8% in the 3rd quarter. Wellington Management Group LLP now owns 602,936 shares of the biopharmaceutical company's stock worth $995,000 after purchasing an additional 241,512 shares during the period. Finally, BNP Paribas Financial Markets grew its holdings in shares of Esperion Therapeutics by 152.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 123,333 shares of the biopharmaceutical company's stock worth $203,000 after purchasing an additional 74,522 shares during the period. Institutional investors and hedge funds own 47.39% of the company's stock.

Esperion Therapeutics Price Performance

NASDAQ:ESPR traded up $0.02 during midday trading on Friday, reaching $2.19. 6,135,917 shares of the company traded hands, compared to its average volume of 6,377,633. Esperion Therapeutics, Inc. has a twelve month low of $1.58 and a twelve month high of $3.94. The company has a fifty day moving average price of $2.42 and a 200 day moving average price of $2.22. The firm has a market capitalization of $431.51 million, a price-to-earnings ratio of -3.42 and a beta of 1.01.

Wall Street Analysts Forecast Growth

ESPR has been the topic of several research reports. Cantor Fitzgerald started coverage on shares of Esperion Therapeutics in a report on Tuesday. They issued an "overweight" rating and a $8.00 price target on the stock. The Goldman Sachs Group started coverage on shares of Esperion Therapeutics in a research report on Wednesday. They set a "neutral" rating and a $4.00 price target for the company. HC Wainwright reiterated a "buy" rating and issued a $16.00 price target on shares of Esperion Therapeutics in a report on Thursday, December 12th. StockNews.com downgraded Esperion Therapeutics from a "buy" rating to a "hold" rating in a research report on Friday, November 15th. Finally, Needham & Company LLC restated a "buy" rating and issued a $6.00 price target on shares of Esperion Therapeutics in a report on Friday, December 13th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $7.30.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.